Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
Publication
, Journal Article
Ohman, EM; Roe, MT
Published in: Thromb Haemost
May 2011
Duke Scholars
Published In
Thromb Haemost
DOI
EISSN
2567-689X
Publication Date
May 2011
Volume
105
Issue
5
Start / End Page
763 / 765
Location
Germany
Related Subject Headings
- United States
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Survival Rate
- Survival Analysis
- Statistics as Topic
- Practice Guidelines as Topic
- Patient Selection
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Ohman, E. M., & Roe, M. T. (2011). Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost, 105(5), 763–765. https://doi.org/10.1160/TH11-03-0159
Ohman, E. M., and M. T. Roe. “Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).” Thromb Haemost 105, no. 5 (May 2011): 763–65. https://doi.org/10.1160/TH11-03-0159.
Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost. 2011 May;105(5):763–5.
Ohman, E. M., and M. T. Roe. “Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).” Thromb Haemost, vol. 105, no. 5, May 2011, pp. 763–65. Pubmed, doi:10.1160/TH11-03-0159.
Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). Thromb Haemost. 2011 May;105(5):763–765.
Published In
Thromb Haemost
DOI
EISSN
2567-689X
Publication Date
May 2011
Volume
105
Issue
5
Start / End Page
763 / 765
Location
Germany
Related Subject Headings
- United States
- Treatment Outcome
- Ticlopidine
- Ticagrelor
- Survival Rate
- Survival Analysis
- Statistics as Topic
- Practice Guidelines as Topic
- Patient Selection
- Humans